Retrospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Apr 28, 2015; 21(16): 4933-4945
Published online Apr 28, 2015. doi: 10.3748/wjg.v21.i16.4933
Table 1 Characteristics of hepatocellular carcinoma patients with hepatitis B virus infection
VariablesAll patients (n = 105)LL group (n = 55)HL group (n = 34)HH group (n = 16)P value
Age (yr)62 (57-68)62 (59-66)64 (56-70)63 (56-70)0.962
Sex, male/female90/1548/729/513/30.829
Body mass index (kg/m2)23.7 ± 3.124.0 ± 2.623.5 ± 3.323.1 ± 4.30.691
Open/pure lap/lap-assisted83/8/1443/6/629/1/411/1/40.390
Hr
0/S/1/2/350/25/14/14/234/13/6/2/014/10/4/4/22/2/4/8/0< 0.001
Preoperative laboratory values
Aspartate transaminase (U/L)31 (22-46)31 (22-41)30 (25-48)43 (24-62)0.153
Alanine transaminase (U/L)29 (20-39)32 (17-42)27 (21-42)27 (19-52)0.978
Platelets (× 104/μL)16.6 ± 13.316.4 ± 12.716.2 ± 16.218.0 ± 8.60.168
Serum ALB (g/dL)3.95 ± 0.463.99 ± 0.463.87 ± 0.433.98 ± 0.530.334
PT (%)93.3 ± 12.295.5 ± 11.190.3 ± 14.192.2 ± 10.60.062
Serum TBIL (mg/dL)0.79 ± 0.440.80 ± 0.450.85 ± 0.490.65 ± 0.240.681
ICGR159.6 (5.7-14.9)9.4 (5.9-14.0)12.5 (5.7-22.5)8.5 (5.0-14.6)0.334
AFP (ng/mL)24.2 (3.8-165.0)5.2 (2.4-31.1)45.0 (5.1-246.5)1950 (753.5-2827.0)< 0.001
DCP (mAU/mL)38 (20-364)22 (15-28)399 (90-1,667)4460 (223-34373)< 0.001
Intraoperative data
Blood loss (mL)400 (130-660)360 (110-560)435 (100-1,040)880 (130-1330)0.042
Surgical duration (min)332 (243-411)313 (236-370)361 (243-450)432 (270-604)0.020
Blood transfusion
RCC: yes/no (%)21/84 (20.0%)4/51 (7.2%)10/24 (29.4%)7/9 (43.8%)0.001
Pathological results
Tumor size (cm)4.27 ± 3.213.26 ± 2.564.97 ± 2.716.24 ± 4.77< 0.001
Multiple tumors: yes/no (%)39/66 (37.1%)19/36 (34.5%)15/19 (44.1%)5/11 (31.3%)0.575
Vascular invasion: yes/no (%)34/71 (32.4%)10/45 (18.2%)14/20 (41.1%)10/6 (62.5%)0.002
Remnant liver: NL/CH/LC13/47/416/23/263/17/144/7/50.464
Histological tumor differentiation
Well/moderately/poorly14/63/2811/35/93/18/130/10/60.048
Recurrence within 2 yr after liver resection
Yes/no (%)50/55 (47.6%)
Table 2 Univariate and multivariate analyses of factors associated with tumor recurrence in patients with hepatitis B virus infection
VariablesUnivariate analysis
Multivariate analysis
HR95%CIP valueHR95%CIP value
Age0.9770.952-1.0030.086
Sex, male1.0770.512-2.2640.843
Preoperative laboratory values
Aspartate transaminase1.0081.003-1.0130.00111.0010.993-1.0100.778
Alanine transaminase0.9990.989-1.0090.811
Platelets1.0010.979-1.0240.929
Serum ALB0.6480.367-1.1420.134
PT0.9740.953-0.9960.02110.9760.946-1.0070.124
Serum TBIL2.3051.346-3.9470.00214.0681.586-10.4360.0041
ICGR151.0331.008-1.0590.01110.9670.919-1.0180.967
Tumor markers
HH group3.2351.673-6.257< 0.00112.4641.086-5.5870.0311
HL group2.0421.164-3.5830.01311.0830.497-2.3600.841
Intraoperative data
Blood loss1.0011.000-1.0010.00211.0001.000-1.0010.416
Surgical duration1.0021.000-1.0040.00311.0000.997-1.0030.868
Pathologic results
Tumor size1.1481.068-1.234< 0.00111.1821.059-1.3180.0031
Multiple tumors1.3631.152-1.612< 0.00111.3360.955-1.8690.091
Vascular invasion2.0881.261-3.4580.00412.6241.408-4.8920.0021
Table 3 Univariate and multivariate analyses of factors associated with poor overall survival in patients with hepatitis B virus infection
VariablesUnivariate analysis
Multivariate analysis
HR95%CIP valueHR95%CIP value
Age0.9960.964-1.0280.797
Sex, male1.4400.511-4.0560.490
Preoperative laboratory values
Aspartate transaminase1.0081.002-1.0140.01211.0040.992-1.0160.518
Alanine transaminase0.9920.976-1.0070.296
Platelets1.0150.994-1.0350.158
Serum ALB0.4690.234-0.9390.033
PT0.9750.950-1.0000.051
Serum TBIL2.2491.125-4.4950.02211.5840.447-5.6130.476
ICGR151.0561.025-1.087< 0.00111.0400.976-1.1080.229
Tumor markers
HH group2.9851.259-7.0750.01312.2740.698-7.4030.173
HL group2.1121.054-4.2320.03511.0250.390-2.6930.960
Intraoperative data
Blood loss1.0011.001-1.001< 0.00111.0001.000-1.0010.391
Surgical duration1.0041.001-1.0080.00511.0020.996-1.0070.534
Pathologic results
Tumor size1.2391.133-1.356< 0.00111.1270.969-1.3100.122
Multiple tumors1.3851.121-1.7110.00211.2000.813-1.7720.358
Vascular invasion2.4911.335-4.6470.00413.1731.352-7.4470.0081
Table 4 Characteristics of hepatocellular carcinoma patients with hepatitis C virus infection
VariablesAll patients (n = 100)LL group (n = 34)HL group (n = 39)HH group (n = 27)P value
Age (yr)71 (62-77)72 (64-77)70 (62-75)70 (65-77)0.766
Sex, male/female82/1822/1229/1016/110.413
Body mass index23.6 ± 3.623.6 ± 2.923.8 ± 3.823.4 ± 4.10.737
Open/Pure Lap/Lap-assisted77/12/1126/3/527/8/424/1/20.218
Hr
0/S/1/2/357/27/11/2/323/8/3/0/021/10/5/1/213/9/3/1/10.784
Preoperative laboratory values
Aspartate transaminase (U/L)47 (30-64)41 (23-56)48 (35-67)53 (47-71)0.101
Alanine transaminase (U/L)38 (26-57)33 (21-53)41 (28-57)42 (29-62)0.496
Platelets (× 104/μL)13.5 ± 6.813.9 ± 4.713.9 ± 9.212.5 ± 4.40.804
Serum ALB (g/dL)3.76 ± 0.393.94 ± 0.403.67 ± 0.353.67 ± 0.380.0061
PT (%)89.8 ± 13.492.5 ± 11.487.8 ± 15.089.2 ± 13.50.254
Serum TBIL (mg/dL)0.78 ± 0.340.74 ± 0.320.79 ± 0.330.81 ± 0.390.777
ICGR1514.2 (8.4-18.5)12.1 (8.1-15.4)14.7 (8.4-21.5)15.6 (13.0-24.6)0.163
AFP (ng/mL)18.6 (5.6-134.0)5.3 (3.8-11.0)21.1 (6.9-99.2)299.7 (68.1-1046.0)< 0.0011
DCP (mAU/mL)45 (21-244)22 (15-35)37 (23-134)429 (124-1902)< 0.0011
Intraoperative data
Blood loss (mL)330 (20-650)263 (70-500)230 (20-500)535 (300-1270)0.0061
Surgical duration (min)304 (230-377)303 (175-377)296 (230-352)345 (282-475)0.0401
Blood transfusion
RCC: yes/no (%)12/88 (12.0%)3/31 (8.8%)2/37 (5.1%)7/20 (25.9%)0.0301
Pathologic results
Tumor size (cm)3.51 ± 2.482.84 ± 1.233.26 ± 2.314.72 ± 3.390.0081
Multiple tumor: yes/no (%)36/64 (36.0%)8/26 (23.5%)17/22 (43.6%)11/16 (40.7%)0.171
Vascular invasion: yes/no (%)30/70 (30.0%)5/29 (14.7%)12/27 (30.8%)13/14 (48.1%)0.0181
Remnant liver: NL/CH/LC5/37/582/18/142027/10/22017/9/10.161
Histological tumor differentiation
Well/Moderately/Poorly17/63/207/23/48/24/72/16/90.213
Recurrence within 2 yr after hepatectomy
Yes/no (%)51/49 (51.0%)
Table 5 Univariate and multivariate analyses of factors associated with tumor recurrence in patients with hepatitis C virus infection
VariablesUnivariate analysis
Multivariate analysis
HR95%CIP valueHR95%CIP value
Age1.0010.972-1.0310.950
Sex, male1.4550.823-2.5700.197
Preoperative laboratory values
Aspartate transaminase1.0050.999-1.0110.134
Alanine transaminase1.0030.966-1.0100.412
Platelets1.0150.983-1.0490.363
Serum ALB0.5690.297-1.0920.090
PT0.9990.980-1.0190.943
Serum TBIL1.2810.610-2.6920.513
ICGR151.0491.017-1.0810.00211.0691.032-1.108< 0.0011
Tumor markers
HH group4.4272.238-8.760< 0.00115.0982.165-12.005< 0.0011
HL group2.2101.166-4.1890.01512.3251.077-5.0180.0321
Intraoperative data
Blood loss1.0011.000-1.001< 0.00111.0000.999-1.0000.292
Surgical duration1.0031.002-1.004< 0.00111.0020.998-1.0060.129
Pathologic results
Tumor size1.2901.178-1.413< 0.00111.1601.033-1.3020.0121
Multiple tumors1.2641.073-1.4870.00511.2641.041-1.5340.0181
Vascular invasion2.4541.479-4.0710.00111.5970.890-2.8670.117
Table 6 Univariate and multivariate analyses of factors associated with poor overall survival in patients with hepatitis C virus infection
VariablesUnivariate analysis
Multivariate analysis
HR95%CIP valueHR95%CIP value
Age1.0250.987-1.0650.195
Sex, male1.3280.668-2.6420.418
Preoperative laboratory values
Aspartate transaminase1.0060.999-1.0130.106
Alanine transaminase1.0010.992-1.0090.849
Platelets1.0360.995-1.0770.084
Serum ALB0.2460.114-0.531< 0.00110.6110.219-1.7060.347
PT0.9940.971-1.0180.643
Serum TBIL1.2060.523-2.7800.660
ICGR151.0541.021-1.0870.00111.0421.001-1.0840.0471
Tumor markers
HH group4.5622.031-10.248< 0.00114.0181.424-11.3370.0091
HL group2.0490.911-4.6090.0832.2090.829-5.8850.113
Intraoperative data
Blood loss1.0011.000-1.001< 0.00111.0000.999-1.0010.727
Surgical duration1.0031.002-1.004< 0.00111.0020.998-1.0050.414
Pathologic results
Tumor size1.2851.162-1.421< 0.00111.0810.946-1.2350.255
Multiple tumors1.2041.021-1.4200.02711.2571.025-1.5420.0281
Vascular invasion2.2231.221-4.0450.00911.0890.490-2.4210.835